Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Unknown 4Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 1780Neoplasms 1500Carcinoma, Non-Small-Cell Lung 1045Prostatic Neoplasms 958Colorectal Neoplasms 882Lung Neoplasms 803Pancreatic Neoplasms 573Carcinoma, Hepatocellular 543Leukemia, Myeloid, Acute 541Stomach Neoplasms 513Ovarian Neoplasms 508Neoplasm Metastasis 499Multiple Myeloma 494Recurrence 412Melanoma 387Squamous Cell Carcinoma of Head and Neck 370Brain Neoplasms 362Uterine Cervical Neoplasms 361Head and Neck Neoplasms 356Esophageal Neoplasms 312Precursor Cell Lymphoblastic Leukemia-Lymphoma 310Lymphoma 306Endometrial Neoplasms 305Triple Negative Breast Neoplasms 299Glioblastoma 299Rectal Neoplasms 282Sarcoma 266Urinary Bladder Neoplasms 264Hematologic Neoplasms 264Colonic Neoplasms 255

Interventions

pembrolizumab 1lenvatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Gastric Adenocarcinoma × Clear all
NCT05041153 2026-01-12

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Recruiting
15 enrolled
Gastrointestinal

Advanced Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡